Cover Image

The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects

Abstract Eslicarbazepine acetate (ESL) is a prodrug antiseizure medication for the treatment of focal seizures. ESL shows a well‐established pharmacokinetic (PK)‐pharmacodynamic relationship and has similar extrinsic epilepsy‐related factors across ethnicities. This study evaluated and compared ESL...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sejung Hwang (Author), Soyoung Lee (Author), Eunwoo Kim (Author), Inyoung Hwang (Author), Joo‐Youn Cho (Author), Jae‐Yong Chung (Author), In‐Jin Jang (Author), Jaeseong Oh (Author)
Format:	Book
Published:	Wiley, 2022-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
by: Woo Kyung Chung, et al.
Published: (2023)

Evaluation of the Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Perampanel in Rats by Isotope-Dilution-UHPLC-MS/MS
by: Liu P, et al.
Published: (2022)

Safety, Tolerability, and Serum/Tear Pharmacokinetics of Human Recombinant Epidermal Growth Factor Eyedrops in Healthy Subjects
by: Hyounggyoon Yoo, et al.
Published: (2022)

Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Nav1.5 Channels
by: Theresa K. Leslie, et al.
Published: (2020)

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
by: Xuanyou Jin, et al.
Published: (2020)

Social cognition and prefrontal cognitive function in patients with epilepsy treated with eslicarbazepine acetate
by: Laura Abraira, et al.
Published: (2017)

Eslicarbazepine acetate: An efficacy and safety as an antiepileptic drug in clinical trials and open studies
by: Martyna Stefaniak, et al.
Published: (2022)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
by: Christopher D. Ma, et al.
Published: (2022)

Development of a stress induced validated UPLC-PDA method for the analysis of Eslicarbazepine acetate
by: Farah Iram, et al.
Published: (2018)

Comments on the Eslicarbazepine Acetate Section of the Article 'Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications'
by: Patricio Soares-, et al.
Published: (2010)

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
by: Kim YK, et al.
Published: (2018)

Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
by: Hwang S, et al.
Published: (2021)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
by: Jiang X, et al.
Published: (2023)

Population Pharmacokinetic Model of AST-001, L-Isomer of Serine, Combining Endogenous Production and Exogenous Administration in Healthy Subjects
by: Soyoung Lee, et al.
Published: (2022)

Clinical utility of eslicarbazepine: current evidence
by: Zaccara G, et al.
Published: (2015)

Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
by: Sunkaraneni S, et al.
Published: (2017)

Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
by: Mehta D, et al.
Published: (2021)

Pharmacokinetics and tolerability of apremilast in healthy Korean adult men
by: Ki Young Huh, et al.
Published: (2021)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
by: Joo Young Na, et al.
Published: (2022)

Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial
by: Sang Kun Lee, et al.
Published: (2024)

Single‐dose of LC51‐0255, a selective S1P1 receptor modulator, showed dose‐dependent and reversible reduction of absolute lymphocyte count in humans
by: Sang Won Lee, et al.
Published: (2022)

Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects
by: Inyoung Hwang, et al.
Published: (2022)

Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males
by: Heejae Won, et al.
Published: (2024)

Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice
by: Mehta D, et al.
Published: (2020)

Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
by: Soyoung Lee, et al.
Published: (2023)

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration
by: Sungyeun Bae, et al.
Published: (2023)

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects
by: Min Young Park, et al.
Published: (2023)

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
by: Martin E Brown, et al.
Published: (2010)

Conventional reversal of rocuronium-induced neuromuscular blockade by sugammadex in Korean children: pharmacokinetics, efficacy, and safety analyses
by: Sang-Hwan Ji, et al.
Published: (2023)

A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)
by: Huafei Tang, et al.
Published: (2024)

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects
by: Seung-Hyun Jeong, et al.
Published: (2020)

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
by: Seung-Hyun Jeong, et al.
Published: (2021)

Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis
by: Hyejin Hwang, et al.
Published: (2018)

Reversal of rocuronium‐induced intense neuromuscular blockade by sugammadex in Korean children: A pharmacokinetic and pharmacodynamic analysis
by: Sang‐Hwan Ji, et al.
Published: (2023)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
by: JungJin Oh, et al.
Published: (2023)

Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea
by: Ki Young Huh, et al.
Published: (2024)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
by: Sejung Hwang, et al.
Published: (2021)

Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESIâIT/MS, 1H, 13C and 1Hâ1H COSY NMR
by: Saji Thomas, et al.
Published: (2014)

Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment
by: Yewon Park, et al.
Published: (2022)

Pharmacokinetic drug-drug interactions of JBPOS0101 mediated by cytochrome P450 3A4 and UDP‐glucuronosyltransferases
by: Sejung Hwang, et al.
Published: (2024)